Seroquel® Combined With Cognitive Remediation Therapy to Conventional Treatment in Patients With Schizophrenia
NCT ID: NCT00255515
Last Updated: 2009-03-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
85 participants
INTERVENTIONAL
2005-09-30
2007-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
SR-Registration Study 1, ROW: Efficacy and Safety of Seroquel® in the Treatment of Patients With Schizophrenia
NCT00206115
A Retrospective Non-interventional Study to Evaluate the Use of Seroquel Extended Release (XR) and Immediate Release (IR) in the Clinical Practice of Inpatients With Schizophrenia
NCT01214135
Seroquel Switching Study: Feasibility of Switching Any Antipsychotic Treatment to Seroquel in Patients With Schizophrenia
NCT00234377
Seroquel (Quetiapine Fumarate) InPractice Evaluation Programme
NCT00921362
Quetiapine Fumarate (SEROQUEL) in the Treatment of Adolescent Patients With Schizophrenia and Bipolar I Disorder
NCT00227305
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
quetiapine fumarate
Quetiapine fumarate
oral
2
Conventional treatment for schizophrenia
conventional treatment for schizophrenia
various standard therapies
3
quetiapine fumarate + Cognitive Remediation Therapy
Quetiapine fumarate
oral
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Quetiapine fumarate
oral
conventional treatment for schizophrenia
various standard therapies
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Documented clinical diagnosis of schizophrenia or schizoaffective disorder for at least 2 years.
* Clinically stable and in an outpatient setting before entering the study (visit 1).
Exclusion Criteria
* If total points are ≤ 55 Intelligence quotient (IQ) according to score of WAIS-III test at visit 1.
18 Years
64 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
AstraZeneca Sweden
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Leif Lindström,
Role: PRINCIPAL_INVESTIGATOR
Västerås
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Eskilstuna, , Sweden
Research Site
Gothenburg, , Sweden
Research Site
Hisingsbacka, , Sweden
Research Site
Huddinge, , Sweden
Research Site
Jönköping, , Sweden
Research Site
Lidingö, , Sweden
Research Site
Limhamn, , Sweden
Research Site
Lund, , Sweden
Research Site
Malmo, , Sweden
Research Site
Norsborg, , Sweden
Research Site
Nyköping, , Sweden
Research Site
Stockholm, , Sweden
Research Site
Trollhättan, , Sweden
Research Site
Umeå, , Sweden
Research Site
Västerås, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SCORE
Identifier Type: -
Identifier Source: secondary_id
D1449L00004
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.